AstraZeneca consensus stays robust, shares in focus on the FTSE 100

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 09:10.

AstraZeneca (GB0009895292) remains one of the largest healthcare names on the London Stock Exchange, with a market capitalization above 210 billion pounds and a key weighting in the FTSE 100 index, according to recent quote data from London.MarketScreener overview of AstraZeneca on the LSE The end of the week brings a clear analyst consensus picture and an established dividend profile after the February 2026 ex-dividend date, setting the frame for investors following the shares.

What analysts say on AstraZeneca

Sell-side coverage for AstraZeneca is broad, with more than 20 major investment banks and research houses publishing regular opinions on the stock, including UBS, JPMorgan and Goldman Sachs, according to consensus summaries.Reuters market page for AstraZeneca in London Aggregated data show a majority of Buy or Outperform recommendations, with a smaller group of Hold ratings and only isolated Underperform views, indicating a broadly constructive stance on the company.

Across these analysts, the average 12?month price target for AstraZeneca shares currently sits meaningfully above the recent London closing price near 13,900 pence, implying upside potential in the low double?digit percentage range according to consensus data providers.Hargreaves Lansdown metrics on AstraZeneca shares Several houses, including large US brokers, have reiterated positive views through the first half of 2026, often citing the oncology pipeline and rare disease exposure via Alexion as core elements of the investment case.

Dividend, valuation and Big Pharma peers

On the income side, AstraZeneca paid a dividend of 1.595 pounds per share with an ex?dividend date on 19 February 2026 and a payment date on 23 March 2026, resulting in a trailing dividend yield of around 1.7 percent at current prices.Dividend and valuation data for AstraZeneca At the same time, the shares trade on a price?earnings ratio close to 28 based on current earnings estimates, placing the stock at a premium to several Big Pharma peers.

Compared with European and US competitors such as GlaxoSmithKline, Novartis and Pfizer, AstraZeneca’s valuation reflects expectations for above?sector growth from its oncology and cardiovascular portfolios, as analysts frequently highlight.Financial Times healthcare sector analysis including AstraZeneca The company’s large index weighting in the FTSE 100 also means many passive and benchmark?oriented investors hold the shares as part of their UK equity and global healthcare allocations.

How AstraZeneca makes its money

AstraZeneca generates most of its revenue from prescription medicines, with oncology, cardiovascular, renal and metabolism, and respiratory diseases as the largest therapeutic areas, according to the company’s latest annual report.AstraZeneca Annual Report and Form 20-F Key products include the lung cancer drug Tagrisso, the diabetes therapy Farxiga and rare disease treatments gained from the Alexion acquisition.

Where the AstraZeneca shares trade today

The AstraZeneca shares (GB0009895292) last traded on the London Stock Exchange at around 13,900 pence on 2026-06-25, 16:35 London time, corresponding to approximately 139 pounds per share at the previous closing auction.

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an invitation to buy or sell securities. Figures and assessments are based on sources considered reliable but cannot be guaranteed. Investors should make decisions based on their own research or consult a professional advisor.